Global Institute of Stem Cell Therapy & Research (GIOSTAR)

What Global Institute of Stem Cell Therapy & Research (GIOSTAR) does

GIOSTAR (Global Institute of Stem Cell Therapy and Research) is a privately held regenerative medicine company headquartered in San Diego, California, that develops and delivers autologous and allogeneic mesenchymal stem cell (MSC) therapies for blood disorders, degenerative diseases, neurological conditions, and COVID-19. The company's core technology is the isolation and processing of MSCs from bone marrow and adipose tissue using proprietary protocols developed by co-founder and Chairman/CSO Dr. Anand Srivastava, with claimed platform extensions into cancer immunotherapy, diabetes, anti-aging, and universal (O-negative) red blood cell production. GIOSTAR operates the world's first dedicated stem cell hospital (125-bed Saviour Hospital, Ahmedabad, inaugurated July 2011) and a Bangalore facility (October 2021), with a 300,000 SF Surat hospital in development in partnership with the Government of Gujarat.

The business operates across three revenue streams: (1) direct patient-paid stem cell treatment services at company-operated hospitals in India, priced on a quote basis that is not publicly disclosed; (2) technology licensing and royalty arrangements with wholly-owned or affiliated regional subsidiaries — GIOWORLD Health Ltd. (UK), GIOWORLD Health Europe Ltd. (EU), Celebration Life Sciences (USA), and GIOCOV (COVID-19) — that conduct clinical trials and commercialization in their respective jurisdictions; and (3) long-term government contracts and MoUs with Indian state governments including Jharkhand (a proposed $2 billion, 15-year program), Gujarat, Madhya Pradesh, and Chhattisgarh to deliver large-scale stem cell transplant programs for sickle cell anemia and other genetic conditions. The company was incubated by Global Private Funding Inc., has planned $180M in EB-5/private equity investment, and is pursuing full regulatory licensing via the FDA, MHRA, and EMA. Key milestones include the April 2020 FDA Compassionate Use approval for COVID-19 treatment and the 2021 launch of GIOCOV targeting Long COVID.

Name

Global Institute of Stem Cell Therapy & Research (GIOSTAR)

Legal name

Global Institute of Stem Cell Therapy and Research

Website

https://giostar.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

51–100 employees

Ownership category

akta.pro rank

Product category

Regenerative Medicine

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical and Diagnostic Laboratories (6215), Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Cell Therapy Clinical Services & Treatment Centers (apheresis, administration, monitoring) (HLAAABAJ), Cell Processing & Ancillary Materials (media, cytokines, beads, vectors, disposables) (HLAAABAH)

Keywords

• Stem cell therapy
• Regenerative medicine
• Cell-based immunotherapy
• Bone marrow transplant
• Autologous cell transplantation

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices5 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Treatment Services: Revenue generated from providing stem cell therapies and treatments to patients at hospital facilities in India and other locations. Treatments include therapies for blood disorders, degenerative diseases, and genetic conditions.
2. Technology Licensing: GIOSTAR licenses its proprietary stem cell technology platforms to subsidiaries and partners including GIOWORLD Health Ltd. (UK), GIOWORLD Health Europe Ltd. (EU), and Celebration Life Sciences (USA) for clinical trials in their respective jurisdictions.
3. Government Contracts: Long-term government contracts for stem cell transplant programs with Indian state governments including Jharkhand ($2 billion over 15 years), Gujarat, Madhya Pradesh, and Chhattisgarh

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Core offering

GIOSTAR provides stem cell-based therapies using mesenchymal stem cells (MSCs) isolated from autologous and allogeneic sources to treat degenerative, genetic, blood-related, neurological, and autoimmune diseases. Treatments are administered through company-operated hospital facilities in India (Ahmedabad and Bangalore) and cover conditions including sickle cell anemia, leukemia, diabetes, Parkinson's, Alzheimer's, multiple sclerosis, muscular dystrophy, and spinal cord injuries. The company also operates a wholly-owned subsidiary (GIOCOV) delivering stem cell-based treatments for acute COVID-19 and Long COVID under FDA Compassionate Use authorization.

Product overview

GIOSTAR is a stem cell therapy and research organization offering a comprehensive portfolio of regenerative medicine treatments. The core offering consists of stem cell-based therapies delivered through hospital facilities (GIOSTAR Saviour Hospital in Ahmedabad, GIOSTAR Hospital in Bangalore), with treatments spanning blood disorders, degenerative diseases, neurological conditions, and metabolic disorders. The company operates GIOCOV, a subsidiary focused on COVID-19 and Long COVID treatments. A major development project includes the world's largest stem cell hospital in Surat, Gujarat. All therapies utilize mesenchymal stem cells isolated from autologous (patient's own body) or allogeneic (matched donor) sources, administered through various methods including local administration, intravenous administration, intrathecal administration, and retrobulbar administration depending on the condition being treated.

Differentiator

Problem solved

Functional benefit

Products and services

• Stem Cell Therapy Services Core offering delivering stem cell-based therapies for degenerative and genetic diseases including blood disorders, autoimmune conditions, neurological diseases, and metabolic disorders, using mesenchymal stem cells administered via local, intravenous, intrathecal, and retrobulbar methods depending on the condition.
• GIOSTAR Saviour Hospital (Ahmedabad) A 125-bed contemporary hospital facility with advanced on-site stem cell laboratory delivering direct medical service to patients with blood disorders and degenerative diseases in India.
• GIOSTAR Hospital (Bangalore) GIOSTAR Hospital in Bengaluru providing stem cell therapy treatments along with cosmetology and aesthetics services through Dr Shetty's MEDSPA.
• GIOCOV COVID-19 Treatment Wholly-owned subsidiary delivering stem cell-based treatments for acute phase COVID-19 and Long COVID syndrome under FDA Compassionate Use authorization, pursuing full regulatory approval from FDA, MHRA, and EMA.

Quantifiable outcome

• First stem cell company worldwide to receive FDA approval for COVID-19 treatment under Compassionate Use Program in April 2020
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Nine partnerships are on record, tiered minor, major and core.

• African Dream Big CorporationminorStrategic or Co-development Partner · 1 January 2022Partnership established in 2021 for nation-building initiatives including advanced healthcare development in African countries starting with Guinea. Co-founder Deven Patel founded African Dream Big Corporation to develop sustainable green economy with infrastructure projects, healthcare, and education.
• GIOWORLD Health Ltd. (UK)majorOEM/ Whitelabel/ Licensing Partner · 1 January 2021Wholly-owned subsidiary created to conduct clinical trials and commercialization of GIOSTAR's proprietary stem cell technology platform in the United Kingdom market.
• GIOWORLD Health Europe Ltd. (EU)majorOEM/ Whitelabel/ Licensing Partner · 1 January 2021Subsidiary established to conduct clinical trials and commercialization of GIOSTAR's proprietary stem cell technology platform in the European Union.
• Celebration Life Sciences (USA)majorOEM/ Whitelabel/ Licensing Partner · 1 January 2021US-based subsidiary created to conduct clinical trials and commercialization of GIOSTAR's proprietary stem cell technology platform in the American market.
• GIOCOVmajorOEM/ Whitelabel/ Licensing Partner · 1 January 2021Wholly-owned subsidiary launched in May 2021 in partnership with TAG Investment Bankers for delivering stem cell-based treatments for acute COVID-19 and Long COVID syndrome. Pursuing full regulatory approval from FDA, MHRA, and EMA.
• Government of Jharkhand, IndiacoreStrategic or Co-development Partner · 14 December 2012State government partnership for sickle cell anemia treatment program. A government delegation including Chief Minister visited San Diego headquarters on December 14, 2012 to finalize proposed $2 billion contract to be serviced over 15 years. Program aims to serve local population suffering from genetic disease.
• Government of Madhya Pradesh, IndiamajorStrategic or Co-development Partner · 1 January 2012MoU signed for developing stem cell transplant programme in the state, announced as part of Vibrant Gujarat Summit follow-up. State government seeking to provide stem cell treatment access to its population.
• Government of Chhattisgarh, IndiamajorStrategic or Co-development Partner · 1 January 2012MoU signed for establishing India's first stem cell research institute in the state. GIOSTAR signing ceremony with Chhattisgarh CM and officials documented in news coverage.
• Government of Gujarat, IndiacoreStrategic or Co-development Partner · 1 January 2011Long-standing partnership for stem cell treatment hospitals. MoU signed in 2009 at Vibrant Gujarat Summit. World's first dedicated stem cell hospital (Saviour Hospital) inaugurated in Ahmedabad in July 2011. Joint development of world's largest 300,000 SF stem cell hospital at Surat Civil Hospital campus. Government signed MoU to establish special organization to free tribal population from sickle cell disease.

Scale indicators9 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Mesoblast: Clinical-stage cellular medicines company developing mesenchymal lineage cell therapies (remestemcel-L) for inflammatory and immune-mediated diseases; the most direct MSC-based therapeutic peer to GIOSTAR's MSC platform.
• Stempeutics Research: India-based stem cell company developing pooled, allogeneic MSC therapies for multiple indications including osteoarthritis and critical limb ischemia; directly comparable geography, technology base, and target disease set to GIOSTAR.
• Athersys: Clinical-stage cell therapy company developing MultiStem (an MSC-like, bone-marrow-derived cell therapy) for stroke, ARDS, and trauma — a direct peer in disease-modifying regenerative cell therapy with the same MSC-adjacent mechanism.
• BrainStorm Cell Therapeutics: Developer of NurOwn, an autologous MSC-based cell therapy for ALS and other neurodegenerative diseases; directly comparable to GIOSTAR's neuropathy, ALS, and muscular dystrophy programs.
• Pluristem Therapeutics: Develops placenta-derived mesenchymal-like adherent stromal cell (PLX) therapies for inflammatory, orthopedic, and vascular indications; competes in the same regenerative cell therapy category as GIOSTAR's MSC platform.
• Capricor Therapeutics: Cell therapy company developing CAP-1002 (cardiosphere-derived cells) for Duchenne muscular dystrophy and COVID-19-related cardiac complications; overlaps with GIOSTAR's muscular dystrophy and COVID-19 treatment programs.
• Vericel: Commercial-stage cell therapy company selling MACI (autologous chondrocytes for cartilage repair) and Epicel (cultured epidermal autografts for severe burns); directly comparable in patient-delivered autologous cell therapy services.
• Cynata Therapeutics: Australia-based clinical-stage company using a proprietary MSC manufacturing platform (Cymerus) to produce consistent allogeneic MSCs at scale; comparable to GIOSTAR's MSC isolation and scale-up approach.
• International Stem Cell Corporation: Stem cell research and therapeutic development company with a clinical pipeline in Parkinson's disease and other neurological conditions; competes in the same MSC/iPSC-adjacent therapeutic space as GIOSTAR.

Emerging players

• Regenexx: U.S. network of clinics delivering autologous stem cell and platelet-rich plasma treatments for orthopedic and musculoskeletal conditions; overlaps with GIOSTAR's osteoarthritis, neuropathy, and orthopedic regenerative offerings at the clinical delivery layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Global Institute of Stem Cell Therapy & Research (GIOSTAR)